In China, toripalimab (240 mg Q3W) in combination with chemotherapy was approved as the first-line treatment for unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations (Wang Z. et al., 2022), recurrent or metastatic nasopharyngeal carcinoma (NPC) (Mai et al., 2021) and advanced esophageal squamous cell carcinoma (ESCC) (Wang Z. X. et al., 2022). This evidence concerns the gene ALK and esophageal squamous cell carcinoma.